Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

March 23 (Reuters) - U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial. Pfizer said it had planned ...
Hoodline

Boston Braces For Ticks As Pfizer Lyme Shot Races The Clock

As another tick season settles in across Greater Boston, Pfizer is betting that its experimental Lyme disease vaccine could eventually change the game. The shot is still in testing and years away from ...